Passage Bio, Inc. (PASG)
Nasdaq · Healthcare · Biotechnology
$4.09−0.73%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $13.2M
- 52-week range
- $3.29 – $20.00
- 52-week change
- −48.18%
- EPS (trailing)
- −$11.30
- Analyst rating
- 2.3 Buy
Fiscal year to Dec 2025
- Net income
- −$45.5M
- Diluted EPS
- −$14.35
From the company’s annual report on SEC EDGAR.
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Headquarters: Philadelphia, United States · 24 employees · passagebio.com